

12. (Amended) The method of treatment of Claim 10 wherein the treatment includes administering the cC1qR binding domain to be effective on complement ubiquitin (CUB) domain functionality.

13. (Amended) The method of treatment of Claim 10 wherein treatment includes administering a therapeutically effective quantity of a complement-ubiquitin-(CUB) domain.

c1 14. (Amended) The method of treatment of Claim 10 wherein treatment includes administering to the mammal a therapeutically effective quantity of a cC1qR binding domain useful in the treatment and maintenance of inflammation.

15. (Amended) The method of treatment of Claim 10 wherein the cC1qR binding domain has the sequence selected from the group consisting of SEQ ID NOS 1- 3.

~~Please cancel claims 16-21.~~

Please add new claims:

22. The method of treatment of Claim 10 wherein the method further includes using an inhibitor of the cC1qR binding domain.

c2 23. The method of treatment of Claim 10 comprising administering a cC1qR binding domain for binding a ligand to inhibit complement activation.

24. The method of treatment of claim 23 further includes inhibiting complement activation involved in the initiation and maintenance of inflammation.

**REMARKS**

To complete the formalities associated with this application, Applicant submits a certified copy of the priority document with this response.